Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Cappato, Riccardo; E. Marchlinski, Francis; H. Hohnloser, Stefan; V. Naccarelli, Gerald; Xiang, Jim; J. Wilber, David; Ma, Changsheng; Hess, Susanne; Wells, Darryl; Juang, George; Vijgen, Johan; Hügl, Burkhard; Balasubramaniam, Richard; de Chillou, Christian; Wyn Davies, D.; Eugene Fields, Larry; Natale, Andrea

doi:10.1093/eurheartj/ehv177

Public

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

Published in European Heart Journal • May 14, 2015

Authors:

Riccardo Cappato

Francis E. Marchlinski

Stefan H. Hohnloser

Abstract

AIMS: VENTURE-AF is the first prospective randomized trial of uninterrupted rivaroxaban and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation (CA). METHODS AND RESULTS: Trial size was administratively set at 250, the protocol-specified...

Subject

Medicine

Rivaroxaban

Atrial fibrillation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!